Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children
NCT: NCT07267689 · RECRUITING
Brief Summary
The purpose of this study is to evaluate the tolerance, the performance and safety of this device, 22‰ Hypertonic seawater aerosol therapy solution in unidose container, to treat adult and peadiatric patients with of upper respiratory tract infection such as rhinopharyngitis, rhinitis, acute rhinosinusitis or cold. The main questions it aims to answer are to assess if the 22‰ Hypertonic seawater solution used as aerosol therapy solution for inhalation: * improve nasal symptoms relief; * improve sleep quality; * improve mucus fluidizing; * is safe and well tolerated. The study is none comparative and will assess prospectively the symptomatic and functional benefits, the tolerance and the general safety of the medical device when used as an aerosol therapy solution, measured by change from baseline. Treatments will be done at home and participants will be required to perform two on sites visits and to complete questionnaires and scales for 7 consecutive days from the treatment starting.
Frequently Asked Questions
What is Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children?
Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children is a clinical trial registered under NCT07267689. Current status: RECRUITING.
What is the status of NCT07267689?
The current status of NCT07267689 (Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children) is: RECRUITING.
When did Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children start?
Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children started on 2026-04-21.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.